ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Syncom Formulations' promoters have voluntarily waived their right to the proposed final dividend of ₹0.10 per share. This waiver reduces total dividend payout obligations.
Syncom Formulations fixed 23 Sep 2026 as record date for a proposed 10% dividend (Rs.0.10/share) pending AGM approval. The 38th AGM is scheduled for 30 Sep 2026.
Syncom Formulations (India) Limited informed exchanges about the dispatch of letters to shareholders with unregistered email addresses, providing instructions to access the 38th AGM Notice and Annual Report.
Syncom Formulations (India) Limited issued notice for its 38th Annual General Meeting, scheduled for 30th September 2026 via Video Conferencing.
Syncom Formulations (India) Limited has filed its 38th Annual Report for the financial year 2025-26, which includes the Notice for the upcoming Annual General Meeting.
Syncom Formulations reported strong Q1 FY27 performance, with revenue rising to ₹125.53 crore and profit after tax reaching ₹24.85 crore. The board recommended a final dividend.
Syncom Formulations (India) Limited announced remote e-voting details for its upcoming 38th Annual General Meeting scheduled for September 30, 2026.
Syncom Formulations appointed M/s M. Goyal & Co. as Cost Auditor and M/s Bansal & Agrawal as Internal Auditor for FY 2026-27.
Syncom Formulation (India) Ltd reported revenue from operations of ₹125.5 Cr (+7.4% YoY) and net profit of ₹24.8 Cr (+57.0% YoY) for Q1 FY27.
Syncom Formulations (India) Limited declared a record date of 23rd September 2026 for the final dividend of Rs. 0.10 per share. The 38th AGM is scheduled for 30th September 2026.
Syncom Formulations approved the financial results for the quarter ended June 30, 2026, declared management changes, and recommended a final dividend of Rs. 0.10 per share.
Syncom Formulations (India) Ltd announced the resignation of Mr. Kedarmal Shankarlal Bankda as Whole-Time Director and Director, effective August 11, 2026.
Syncom Formulations (India) Limited will hold a board meeting on August 11, 2026, to consider quarterly financial results and dividend recommendations.
Syncom Formulations India Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulations.